Breakthrough in Gene Therapy for Rare Immune Disorder SCID

Strategic Insights -

Gene therapy for Severe Combined Immunodeficiency (SCID), a rare inherited immune disorder, has faced significant challenges, particularly for RAG-deficient SCID. However, a recent patent filing by Laura Garcia-Perez, Arjan C. Lankester, Karin Pike-Overzet, Frank J. T. Staal, and Marja C. J. A. Van Eggermond from the Academy Hospital Leiden (H.O.D.N. Lumc) presents a promising approach using optimized RAG1 deficient gene therapy.

The background of SCID is critical to understanding the urgency for new therapeutic strategies. SCID patients experience severe infections, pneumonia, meningitis, and sepsis due to impaired immune function, often resulting in significant morbidity and mortality. The current treatment, allogeneic stem cell transplantation, carries risks of graft-versus-host disease and limited curative potential for RAG-deficient SCID. Gene therapy has shown promise for SCID patients with ADA-SCID and X-linked SCID, but with risks of insertional mutagenesis.

The inventors have designed lentiviral SIN plasmids that allow for efficient expression of a codon-optimized RAG1 transgene sequence. These plasmids ensure a minimum threshold of RAG1 expression required for a therapeutic effect, significantly reducing the risk of insertional mutagenesis. In a preclinical Rag1-/- model, mice with low RAG1 expression showed poor immune reconstitution, while high RAG1 expression resulted in phenotypic and functional lymphocyte reconstitution comparable to mice receiving wild-type stem cells.

Key Takeaways:

  • The inventors have designed a lentiviral SIN plasmid that ensures a minimum threshold of RAG1 expression required for a therapeutic effect in treating RAG-deficient SCID, thereby reducing the risk of adverse effects.
  • The codon-optimized RAG1 transgene sequence and the MND promoter operably linked to the expression cassette generate RAG expression at a level at least three-fold higher than the expression of the housekeeping gene ABL in a CD34+ hematopoietic stem cell.
  • The use of low copy number plasmids significantly reduces the incidence of insertional mutagenesis during gene therapy, making it a safe and effective approach for treating SCID patients.
  • The lentiviral plasmid can be produced at higher titres compared to other LV backbones, facilitating clinical translation.
  • The inventors have demonstrated a beneficial effect in treating RAG1 deficient SCID using the optimized gene therapy, suggesting its clinical potential.
  • Gene therapy for RAG-deficient SCID can provide a curative option with fewer adverse effects compared to current treatments.

Statistics:

  • The preclinical Rag1-/- model demonstrated a minimum threshold of RAG1 expression required for a therapeutic effect, which is at least three-fold higher than the expression of the housekeeping gene ABL.
  • Low RAG1 expression showed poor immune reconstitution, while high RAG1 expression resulted in phenotypic and functional lymphocyte reconstitution comparable to mice receiving wild-type stem cells.
  • The incidence of insertional mutagenesis during gene therapy is significantly reduced using low copy number plasmids.

Sources:

  • Garcia-Perez, Laura. Optimised RAG1 deficient gene therapy. U.S. Patent Number 12440579, filed March 6, 2020, and published online on October 14, 2025.
  • (https://ppubs.uspto.gov/pubwebapp/external.html?q=(12440579)&db=USPAT&type=ids)